Edgewise Therapeutics 관리

관리 기준 확인 4/4

Edgewise Therapeutics CEO는 Kevin Koch, Aug2017 에 임명되었습니다 의 임기는 7.25 년입니다. 총 연간 보상은 $ 3.98M, 15% 로 구성됩니다. 15% 급여 및 85% 보너스(회사 주식 및 옵션 포함). 는 $ 11.66M 가치에 해당하는 회사 주식의 0.37% 직접 소유합니다. 11.66M. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 4.8 년입니다.

주요 정보

Kevin Koch

최고 경영자

US$4.0m

총 보상

CEO 급여 비율	15.0%
CEO 임기	7.3yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Nov 26

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Sep 19

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Aug 12

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Aug 05

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

May 10

Edgewise Therapeutics: Behind The Massive Rally

Feb 18

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Dec 07

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Aug 16

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Apr 28

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Jan 13

Edgewise Therapeutics proposes $100M stock offering plan

Sep 13

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Aug 04

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Aug 02

CEO 보상 분석

Kevin Koch 의 보수는 Edgewise Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$124m
Jun 30 2024	n/a	n/a	-US$116m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$4m	US$595k	-US$100m
Sep 30 2023	n/a	n/a	-US$89m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$76m
Dec 31 2022	US$5m	US$572k	-US$68m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$51m
Dec 31 2021	US$5m	US$525k	-US$43m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$27m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$2m	US$425k	-US$17m
Dec 31 2019	US$741k	US$425k	-US$10m

보상 대 시장: Kevin 의 총 보상 ($USD 3.98M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 6.54M ).

보상과 수익: Kevin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kevin Koch (64 yo)

7.3yrs

테뉴어

US$3,975,855

보상

Dr. Kevin Koch, Ph.D. is a Venture Partner at OrbiMed Advisors, LLC. He has been a Member of Scientific Advisory Board at OnKure, Inc. Dr. Koch serves as a Member of Scientific Advisory Board at Frontier M...

리더십 팀

이름	위치	테뉴어	보상	소유권
Peter Thompson	Co-Founder & Independent Chairman	7.5yrs	US$226.00k	0% $ 0
Kevin Koch	President	7.3yrs	US$3.98m	0.37% $ 11.7m
Badreddin Edris	Co-Founder & Independent Director	7.5yrs	US$193.00k	0.021% $ 654.0k
Behrad Derakhshan	Chief Business Officer	4.2yrs	US$1.76m	0.016% $ 499.0k
Joanne Donovan	Chief Medical Officer	3.6yrs	US$1.72m	0.015% $ 479.6k
Alan Russell	Co-Founder	7.4yrs	US$2.46m	0.013% $ 419.7k
R. Carruthers	Chief Financial Officer	4.2yrs	US$772.02k	0.081% $ 2.5m
John Moore	General Counsel	4.2yrs	데이터 없음	0.0034% $ 107.2k
Marc Semigran	Chief Development Officer	1.9yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 관리: EWTX 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter Thompson	Co-Founder & Independent Chairman	7.5yrs	US$226.00k	0% $ 0
Kevin Koch	President	7.4yrs	US$3.98m	0.37% $ 11.7m
Badreddin Edris	Co-Founder & Independent Director	3.8yrs	US$193.00k	0.021% $ 654.0k
Alan Russell	Co-Founder	7.3yrs	US$2.46m	0.013% $ 419.7k
Jonathan Root	Independent Director	5.3yrs	US$199.50k	0.017% $ 515.6k
Laura Brege	Independent Director	3.9yrs	US$208.00k	0% $ 0
Arlene Morris	Director	less than a year	데이터 없음	데이터 없음
Barry Byrne	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Leslie Leinwand	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jonathan Fox	Independent Director	1.7yrs	US$485.00k	0.011% $ 358.4k
Lee Sweeney	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Craig McDonald	Member of the Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: EWTX 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Edgewise Therapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

General Counsel exercised options and sold US$1.9m worth of stock

Chief Financial Officer recently sold US$830k worth of stock

Chief Financial Officer notifies of intention to sell stock

High number of new directors

Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors

Edgewise Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Price target increased by 11% to US$45.86

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

New major risk - Revenue and earnings growth

Edgewise Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

General Counsel exercised options and sold US$1.9m worth of stock

Chief Financial Officer recently sold US$830k worth of stock

Chief Financial Officer notifies of intention to sell stock

New major risk - Share price stability

Price target increased by 11% to US$36.67

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Edgewise Therapeutics, Inc Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Edgewise Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New major risk - Revenue and earnings growth

Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

High number of new directors

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors

Edgewise Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Edgewise Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Price target increased by 16% to US$30.50

Edgewise Therapeutics: Behind The Massive Rally

Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

General Counsel notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $240.000002 million.

General Counsel notifies of intention to sell stock

Co-Founder recently sold US$1.6m worth of stock

Co-Founder notifies of intention to sell stock

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

New major risk - Revenue and earnings growth

Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)

Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Price target increased by 17% to US$27.40

Edgewise Therapeutics, Inc. Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

New minor risk - Share price stability

Price target increased by 15% to US$27.40

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Price target increased by 19% to US$28.75

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics, Inc. Appoints Marc Semigran as Chief Development Officer

Edgewise Therapeutics Announces Initiation of Lynx Phase 2 Clinical Trial of Edg-5506 for the Treatment of Duchenne Muscular Dystrophy

Edgewise Therapeutics, Inc. Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy

Edgewise Therapeutics proposes $100M stock offering plan

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

General Counsel notifies of intention to sell stock

Edgewise Therapeutics, Inc. Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy

General Counsel exercised options and sold US$74k worth of stock

Price target increased to US$30.00

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics Now Enrolling Canyon Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

General Counsel exercised options and sold US$65k worth of stock

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2000 Growth Index

Edgewise Therapeutics Inc. Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular

General Counsel exercised options and sold US$226k worth of stock

Price target decreased to US$25.60

General Counsel notifies of intention to sell stock

Price target increased to US$31.00

Edgewise Therapeutics, Inc. Anticipates Initiation of Phase 2 Trials in Individuals with BMD (NCT05291091) in the Second Quarter of 2022 and BMD in the Second Half of 2022

High number of new directors

Edgewise Therapeutics, Inc. Announces the Initiation of an Edgewise-Funded Observational Trial in Individuals with BMD